Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Aptevo Therapeutics Inc. | apvo-ex322_53.htm |
| EX-32.1 - EX-32.1 - Aptevo Therapeutics Inc. | apvo-ex321_54.htm |
| EX-31.2 - EX-31.2 - Aptevo Therapeutics Inc. | apvo-ex312_52.htm |
| EX-31.1 - EX-31.1 - Aptevo Therapeutics Inc. | apvo-ex311_49.htm |
| EX-21.1 - EX-21.1 - Aptevo Therapeutics Inc. | apvo-ex211_50.htm |
| 10-K - 10-K - Aptevo Therapeutics Inc. | apvo-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 No. 333-213108) pertaining to the Converted Equity Awards Incentive Plan and 2016 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
(2) |
Registration Statement (Form S-8 No. 333-219875) pertaining to the 2016 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
(3) |
Registration Statement (Form S-8 No. 333-226717) pertaining to the 2018 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
(4) |
Registration Statement (Form S-3 No. 333-221499) of Aptevo Therapeutics Inc., and |
|
|
(5) |
Registration Statement (Form S-3 No. 333-229115) of Aptevo Therapeutics Inc.; |
of our report dated March 25, 2020, with respect to the consolidated financial statements of Aptevo Therapeutics Inc. included in this Annual Report (Form 10-K) of Aptevo Therapeutics Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Seattle, Washington
March 25, 2020